Document is current
Any future updates will be listed below
-
Authors
Staaf, Johan https://orcid.org/0000-0001-5254-5115
Häkkinen, Jari https://orcid.org/0000-0002-8466-9179
Hegardt, Cecilia
Saal, Lao H. https://orcid.org/0000-0002-0815-1896
Kimbung, Siker https://orcid.org/0000-0002-7001-8367
Hedenfalk, Ingrid https://orcid.org/0000-0002-6840-3397
Lien, Tonje
Sørlie, Therese https://orcid.org/0000-0002-5995-2319
Naume, Bjørn
Russnes, Hege
Marcone, Rachel
Ayyanan, Ayyakkannu https://orcid.org/0000-0003-2496-0025
Brisken, Cathrin https://orcid.org/0000-0002-6857-3230
Malterling, Rebecka R.
Asking, Bengt
Olofsson, Helena
Lindman, Henrik
Bendahl, Pär-Ola https://orcid.org/0000-0001-8862-1845
Ehinger, Anna https://orcid.org/0000-0001-9225-7396
Larsson, Christer
Loman, Niklas
Rydén, Lisa https://orcid.org/0000-0001-7515-3130
Malmberg, Martin https://orcid.org/0000-0002-9500-8982
Borg, Åke https://orcid.org/0000-0002-5793-132X
Vallon-Christersson, Johan
-
Funding
Funding for this research was provided by:
Cancerfonden (CAN 2021/1407)
Vetenskapsrådet (2021-01800)
- License Information
-
More Information
Article History
Received: 26 January 2022
Accepted: 20 July 2022
First Online: 16 August 2022
Competing interests
: All authors declare no competing financial interests related to the study, and for all but A.E., H.L., and L.H.S. also no competing non-financial interests. A.E., H.L., and L.H.S. declare the following competing non-financial interests for this study: A.E. has received speakers’ honoraria from Novartis, Amgen, Roche, and advisory board fees from Roche. H.L. reports honoraria for lecturing from Astra-Zeneca, Novartis, Lilly, and Seagen, and working in advisory boards of Pfizer, Novartis, Daiichi, MSD, Amgen, and Pierre Fabre, and has received research support from Roche. L.H.S. has employment and ownership interest (including stock and patents) in SAGA Diagnostics AB.
